^
Association details:
| Biomarker: | SH2B3 alteration |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Pediatric Acute Lymphoblastic Leukemia: Regimen components…Consolidation…For CRLF2+ or CRLF2- with JAK2 fusions, EPOR rearrangement, SH2B3 alterations, IL7R insertions/deletions: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + ruxolitinib; IT therapy: methotrexate
Secondary therapy:
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase + DR6MP
